

Contents

Introduction	1
<i>A. Schneeweiss</i>	

I. Quality of Life

The Pathophysiological Basis, Clinical Presentation, and Therapy of Chronic Heart Failure. With 7 Figures	5
<i>M. Böhm and E. Erdmann</i>	

On the Epidemiology of Heart Failure	27
<i>H. Viefhues</i>	

Mortality Versus Quality of Life	33
<i>R. Rychlik</i>	

Quality of Life Assessment in Congestive Heart Failure: Points of View from a Cardiologist and a Psychologist. With 1 Figure	41
<i>P. G. Hugenholtz and R. A. M. Erdman</i>	

From Heaven Through the World to the Earth	58
<i>H. Viefhues</i>	

Quality of Life: Semantic History, Political and Scientific Terminology, Measurement and Methodology, Medical Research	66
<i>H. Viefhues</i>	

Measuring the Quality of Life in Patients with Heart Failure: Basic Principles, Methods, and Use in Clinical Studies	92
<i>M. Bullinger and E. Pöppel</i>	

Quality of Life after Bypass and Valvular Surgery: Results of a Prospective Study. With 1 Figure	104
<i>M. Bullinger and D. Naber</i>	

Guidelines for Improving Prognosis, Stress Tolerance, and Quality of Life in Patients with Heart Failure: Cardiological and Psychological Aspects	118
<i>G. F. Hauf and W. Langosch</i>	

Quality of Life of Infants and Children with Cardiac Disease and Cardiac Failure Both Before and After Cardiac Surgery. With 5 Figures . . .	132
<i>E. W. Keck</i>	

Health Care and Economic Aspects of the Quality of Life of Heart Failure Patients. With 2 Figures	149
<i>W. Pohl and J.-M. Graf von der Schulenburg</i>	

The Questionnaire as a Tool for the Empirical Assessment of Quality of Life in Patients with Cardiac Failure	165
<i>R. Rychlik, D. Urbahn, and P. Potthoff</i>	

Quality of Life: A Relevant Endpoint. With 8 Figures . . .	172
<i>H. Troidl</i>	

Prevention: The Risk Factor Model and Life-Styles Relevant to Health. With 2 Figures	186
<i>J. von Troschke</i>	

II. Nitrate Therapy

The Role of Nitrates in Congestive Heart Failure. With 1 Figure	197
<i>J. Abrams</i>	

Chemical Pathways Proposed for the In Vitro Metabolism of Nitrovasodilators and Their Conversion into Vasoactive Species. With 6 Figures	203
<i>M. Feelisch and E. Noack</i>	

Effect of Intravenous Isosorbide Dinitrate Versus Nitroglycerin in Patients with Acute Myocardial Infarction and Elevated Pulmonary Artery Wedge Pressure. With 1 Figure	220
<i>G. B. Cintron and S. P. Glasser</i>	

Effects of Isosorbide-5-Mononitrate on Haemodynamics and Exercise Tolerance in Patients with Heart Failure: Comparisons with Digoxin and Placebo. With 2 Figures	227
<i>I. Dews, C. Marks, D. Woodings, J. Stephens, and M. VandenBurg</i>	
Improved Left Ventricular Geometry and Function by Prolonged Nitroglycerin Therapy After Acute Myocardial Infarction. With 4 Figures	236
<i>B. I. Jugdutt, B. L. Michorowski, and W. T. Tymchak</i>	
Intravenous Nitroglycerin in Acute Myocardial Infarction. With 4 Figures	242
<i>B. I. Jugdutt</i>	
Effects of Intravenous Nitrates in Acute Myocardial Infarction	254
<i>Dž. E. Rezaković, G. Popović, M. Popadić, J. Štalec, and L. Pavičić</i>	
Hemodynamic Effects of a Subchronic Therapy with 120 mg Isosorbide Dinitrate Slow-Release in Coronary Artery Disease and Left Heart Failure. With 5 Figures	265
<i>R. Wolf, A. Nötges, U. Traber, and R. Sinn</i>	
Isosorbide Dinitrate and Nitroglycerin Oral Spray in Heart Failure	272
<i>A. Schneeweiss, A. Marmor, and L. Reisin,</i>	
Nitrates in Heart Failure. With 2 Figures	276
<i>B. Rabinowitz</i>	